Seamless GMP Cell Separation: Healthier Cells, Better Therapies. Akadeum’s microbubble technology is the first GMP cell separation modality to solve all the challenges in the early steps of the cell therapy manufacturing process: time, cost, scalability, and performance. Microbubbles are flexible to integrate into any workflow and provide an increase in potency and persistence while enabling up to a 40% reduction in overall cell therapy manufacturing costs. Compatible with both centralized and decentralized manufacturing models, utilizing microbubbles for cell separation is the path to greater access and more cost-effective therapeutics. Healthier Cells. Better Therapies. Microbubble Cell Separation, Cell Therapy, and …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

344 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

274 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA. Microbial Therapeutics, Host Microbe Interactions, Human Microbiome, and Pharmaceutical Development

271 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A preclinical-stage drug-development company specialized in neuro-oncology GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year. To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs. GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights. GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan: Louis-Marie is a biotech entrepreneur with 15 years of experience …

59 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

311 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to discover, develop and deliver next generation cancer therapies. G1 Therapeutics, Inc. is a wholly owned subsidiary of Pharmacosmos. Cancer / Oncology, Drug Discovery and Development, and Biotechnology

140 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotechnology company who supports scientists worldwide with high-end human cell culture products and services. At PromoCell, we help scientists do better research with a world-class portfolio of human primary, stem and blood cells as well as optimized cell culture media. With over 35 years of expertise, we are recognized globally for supplying scientists with the tools and support they need to do groundbreaking research. All our products comply with European biomedical conventions, ensuring human rights and donor privacy are always protected. Our ISO certifications demonstrate our absolute commitment to quality and our EXCiPACTTM GMP certification enables us to produce …

141 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Portuguese start up developing a relevant position across the product and business value chains of cellular agriculture. We are kickstarting Cell-Based Agriculture in Portugal. Our team aims to create a network of businesses that will lead the market in the next decade driven by technical knowledge on Cell-Based protein production.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Enabling manufacture of cell therapies at scale Cell therapy manufacturing was never designed to scale. Cellular Origins is changing that. We enable the manufacture of cell therapies at commercial scale through a flexible, factory-led approach. Our platform, Constellation, combines mobile robotics and AI to orchestrate the movement of patient material, equipment, and processes across the entire facility, while integrating with your leading bioprocessing technologies. By replacing fixed, linear systems with modular, parallelisable design, we enable intelligent capacity planning, built-in redundancy, and seamless scale-up without process redesign. The result is lower risk, greater efficiency, increased flexibility, and a faster path to …

111 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

344 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Cellesce specialises in the development, scale up and manufacture of PDOs (patient-derived organoids) Cellesce Ltd is a biochemical engineering company based in Cardiff in the UK. Cellesce specialises in the development, scale up and manufacture of organoids (PDOs). Cell expansion, Organoid culture, Drug discovery, Oncology, Bioprocess, and 3D Cell Culture

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative Manufacturing Services (IMFS).

176 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

When precision matters Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including ThermoguideTM Workstation and sterile disposables, for minimally invasive laser ablation of soft tissue, cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. CLS aims at expanding the current approvals to also include treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal treatment effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Igyxos develop more effective/efficient infertility treatment for patients Igyxos is a biotechnology company based out of CENTRE INRAe VAL DE LOIRE SITE DE TOURS, NOUZILLY, France. Biotechnologie, Fertilité, and anticorps monoclonal

180 similar entities Type: SMB Activities: biotech healthtech Technologies: Synthetic Biology

IPRASENSE delivers Automated Cell Count & Viability Analyzers as well as time‐lapse imaging/analysis inside incubators IPRASENSE revolutionizes cell analysis with innovative technologies for automated cell counting and real-time visualization, ideal for research and quality control. Cell Count, Viability, Lensless, Holography, Cell Culture Monitoring, High Throughput, low sample volume, Fast count, sample preparation free, Automation Integration, and Label free

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

227 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your Cell-Therapy Specialized CDMO Cell-Easy is a CDMO specialized in Cell Therapy. We support biotech, pharma, and public institutions with GMP development and manufacturing. Our mission: accelerate your Cell Therapy’s path to market, with patient access as our priority. ATMPs are not conventional biologics — they are living drugs. Our team brings hands-on expertise in cell culture across all cell types, engineered or not, addressing challenges in development, GMP manufacturing, and QC. Beyond core CDMO services — process diagnostics, development, GMP production, cell banking, cryostorage, and delivery — we also support sourcing of human biological materials and clinical trial setup, …

200 similar entities Type: Startup Activities: biotech healthtech manufacturing Technologies: Synthetic Biology

Soft culture plates for pleased cells Cell&Soft is a young french biotech located in the AURA region, in Grenoble city. Born from a joint project between LTM Lab (CNRS) and CEA BIG, Cell&Soft is specialized in the development, production and sale of soft and biomechanical substrates for in vitro cell culture. Cell&Soft offers solutions to enhance the physiology and the relevance of cell culture and cell-based assays. biotechnology, cell culture, soft substrates, culture plates, cell-based assays, biotech, in vitro, drug discovery, stem cells, controlled rigidity, controlled stiffness, and petri dish

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Created in 2017, Cyprio is founded on ten years of research at the prestigious French institute for higher education in science and engineering, Ecole Supérieure de Physique et Chimie Industrielles de la ville de Paris (ESPCI Paris), with a strong expertise in the field of 3D cell culture, liver biology and drug development. This makes Cyprio the holder of a unique technology for fabrication of alginate liquid-core capsules containing 3D cellular models physiologically more relevant than traditional monolayer cell culture and compatible with high throughput screening applications. Our first product "HepatoPearl" has been validated as a beneficial in vitro liver …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Now a part of Catalent Cell & Gene Therapy With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. …

60 similar entities Type: Startup Activities: deeptech manufacturing biotech Technologies: Synthetic Biology

Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation

380 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Repair the liver without graft GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation. GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research

138 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell therapy Acceleration and Innovation: Rethinking cell & gene therapy By Institut Curie CellAction (Cell therapy Acceleration and Innovation) is the cell and gene therapy platform of the Paris-Saclay Cancer Cluster (PSCC) at Institut Curie. A first in France, CellAction enables collaborative projects to be launched with industrial partners on a national and international scale. The aim is to accelerate the development of optimized cell and gene therapies. CellAction is founded on the centralization of key expertise required for the drug development process: - Institut Curie's highly qualified medical-scientific teams - Cutting-edge technologies for in vitro and in vivo testing …

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell Signaling Technology for Organ Repair and Regeneration Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem Cell therapy, Acquired liver diseases, Liver diseases, liver based genetic diseases, NASH, ACLF, Antibodies, Clinical stage, Chronic liver disease, Fatty liver, Acute liver disease, Regenerative medicine, Biotech, and Biotechnology

94 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Making it possible CLEAN BIOLOGICS is a CDMO for Viral vectors, Viral vaccines and oncolytic viruses and Biosafety testing for biological products. As well as a CMO for MCB & WCB production. GMP compliance

95 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

385 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

A stem cells Contract Development and Manufacturing Organisation (CDMO) in Singapore. MSC, iPSC, clean meat. SingCell offers process development and contract manufacturing services for stem cell therapy and clean meat companies. SingCell leverages its proprietary technology to improve manufacturing processes and offer high consistent quality stem cells. #cleanmeat #celltherapy

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

264 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Trustworthy development and commercial manufacturing of CELL&GENE therapies CELLforCURE by SEQENS, based near Paris, is a leader in the manufacturing of Advanced Therapy Medicinal Products (ATMPs), specialized in both autologous and allogeneic cell and gene therapy solutions. With over a decade of expertise, we provide comprehensive end-to-end services, from Phase I to full-scale commercial production. Our cutting-edge “one-stop-shop” facility spans 10,000 sqm, including 2,200 sqm of GMP-certified production areas and 7 independent manufacturing lines, each equipped with 8 cleanrooms, ensuring maximum safety and compliance for every product. As a trusted comprehensive solution provider, we facilitate seamless project development, leveraging in-house …

68 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ready-to-use cell bank, for research, for patients Lymphobank - ready-to-use cell bank, for research, for patients. Lymphobank is a biotech company specializing in the supply of adult and placental blood cells for research use, the characteristics of which will be available online (www.lymphobank.fr), making it possible to choose the cellular product based on a donor of interest. Our services are focused on the development of cellular immunotherapy products. Furthermore, Lymphobank is developing an innovative allogeneic adoptive immunotherapy approach for hepatocellular carcinoma (the most common liver cancer and second cause of cancer death in the world, with nearly 750,000 deaths per …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

72 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We were made for this 53Biologics is a end-to-end biologics CDMO built to keep progress moving. By combining scientific expertise, integrated in-house capabilities and a collaborative way of working, we enable confident decision-making as biologics programs evolve. We support your biologic from early development to commercialization. With USP and DSP development, GMP manufacturing, quality control and fill-finish connected under one roof, we reduce handoffs, protect continuity and help clients grow without disruption. We were made for this. Biopharmaceuticals , CDMO, pDNA, Recombinant Protein, GMP, Drug Development, Microbial Manufacturing, Cell Banking, and GMP Manufacturing

353 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

iPSC-first CDMO. Manufacturing services & platforms for iPSC-derived cell therapy and regenerative medicine Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit …

79 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing Medecine Together Creapharm is now Myonex - Myonex is an industry leader in global clinical trial supply and pharmaceutical commercial services. Our suite of integrable services and solutions helps pharmaceutical, biotech, and CRO partners advance medicine by reducing time, costs, and complexity. With locations in the US, Germany, UK, and France, our comprehensive, client-focused approach, coupled with expert project management, ensures seamless execution across regions, optimizes supply chain efficiency, and adapts to evolving trial or project needs while delivering quality, flexibility, and global scale. Learn more at www.myonex.com. Clinical GMP Production, Clinical Packaging, Distribution Distribution, International Depot Network, IMP …

211 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

296 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

We are your responsive, reliable, and resourceful CDMO Partner. Streamline your biomanufacturing programs with Cytovance Biologics! Born from a decades-long history in drug development, we believe in creating a healthier world where every biologic’s path to commercialization is advanced by a CDMO partner that delivers ingenuity end-to-end. Whether your large molecule product needs the flexibility of a customized approach or the efficiency of a predetermined platform process, Team Cytovance has the deep expertise in microbial and mammalian expression systems to support your scale-up at every stage. From early needs like cell line development and strain selection to cGMP manufacturing for …

192 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

348 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LIVE CELL SHIPMENT Cellbox Solutions develops innovative logistics solutions for the global BioMed industry. Its flagship product, a portable incubator with active CO2 and temperature control, ensures the safe transport of living cells and biological samples under optimal laboratory conditions. The concept originated at Fraunhofer EMB in Lübeck, where researchers needed a solution to transport fragile biological material and cells while maintaining constant conditions of 37°C and 5% CO2. Within 18 months, a team of engineers and biologists developed fully functional and robust CellboxTM. Today, Cellbox Solutions collaborates closely with more than 150 customers to tackle diverse cell transport challenges …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Automation and standardization of cryopreservation processes for Cell Therapies Cellulis (formerly ZF Biotox) provides disruptive cryopreservation technologies in a broad range of biotechnology fields aiming to innovate CELL THERAPY solutions, to streamline BIOPROCESSING production, to enhance BIOBANKING and to improve High Throughput Screening (HTS) campaigns. Frozen Cells in Microplates Ready to Use., Final product formulation for cryopreserved cell therapy, and Cryopreservation of Cell Therapies

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Acquired by Evotec SE in July 2022, Rigenerand is now operating as Evotec (Moderna) Srl. Originating as a start-up from the University of Modena and Reggio Emilia developing and producing innovative products for pre-clinical and clinical applications of cell-based technologies for regenerative medicine and oncology, the cell technology company aims to fill therapeutic gaps for the many still incurable diseases by manufacturing smart treatments based on gene-modified cells with a specific focus on cancer With its team of leading cell therapy experts, Evotec (Moderna) adds a high-quality cGMP manufacturing site to the EVOcells platform increasing capacity, critical expertise, and capabilities …

160 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

109 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

561 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences

214 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Transforming Therapeutic Manufacturing Codexis is redefining what is possible in therapeutic development and manufacturing, leading the technology revolution with efficient, high-quality, and commercially proven solutions. The company’s manufacturing platforms consistently outperform legacy methods, enabling the development of therapeutic possibilities that were previously out of reach. With a proven track record, proprietary technology, and unrivalled scientific expertise, Codexis advances beyond conventional boundaries. More than a solutions provider, Codexis serves as a trusted long-term partner, committed to driving progress across complex therapeutic development and manufacturing. Biocatalysis, Directed Evolution, Enzyme Optimization, Biocatalysts, Enzyme Engineering, API manufacturing, Pharmaceutical manufacturing, RNA manufacturing, RNA detection, Oligo …

68 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

589 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bridging research and translation for a healthy future. ImmuneBridge is building a world where high quality cell therapies can be rapidly designed and easily manufactured at commercial scale and ultralow cost. Cell Therapy, Immunotherapy, CAR-NK, Natural Killer Cells, and Oncology

182 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

370 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Develop human organ models with true physiological complexity We are specialized in the production and development of human, immunocompetent Organ-on-Chip technology for in vitro disease and infection modelling. Organ-on-Chip, Human Cell Biology, Infection, Infectious disease, Toxicity profiling, Immune Cell Interactions, Inflammatory Diseases, Antibody recycling, and Uptake / Transport studies

263 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Transforming Energy into Therapy Galvanize Therapeutics is developing therapies to deliver life-changing healthcare solutions to patients and their doctors at the convergence of biology, engineering, and care delivery. medical device, COPD, AF, Oncology, Intervential Oncology, Intervential Pulmonology, AFib, PEF, PEF Ablation, Soft Tissue Ablation, Cardiac Arrhythmias, and Chronic Bronchitis

451 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity.

110 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative Biosurgery Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up develops and commercializes hemostatic products based on patented biopolymers designed to simplify traditional and laparoscopic surgical procedures in numerous specialties such as cardiac, general and orthopedic, and give patients a better quality of life. The Company’s lead product, HEMOBLASTTM Bellows, is marketed in Europe and the United States. Biotechnologie, Dispositifs Médicaux Implantables, Collagène, Equipements médicaux, Hémostase, Innovative biosurgery, Medical devices, Hemostasis, Collagen, Biotechnology, Pharmacy, Hemoblast, hemostatic, medical devices, and hemostasis

220 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Solution for biologics Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products. biosafety testing, Cell Banking and Storage, Viral Clearance, Potency Assay, R&D Contract, Training, …

102 similar entities Type: SMB Activities: biotech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

634 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

miRNA-enhanced Extracellular Vesicles Therapeutics ConvEyXO, founded in 2019 by veterans of pharma industry, builds a specialized technology platform to convey exosome-based therapeutics to the market. The company is developing is therapeutic portfolio in the field of fibrosis and chronic inflammatory disorders. The rapid development of the company is the result of collaborations with partners with a demonstrated track record in healthtech and biotech fields manufacturing, process development, upstream, downstream, extracellular vesicles, exosomes, therapeutics, cargo, Loading, 4D, and exosomes

444 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the future of medicine® We support the advancement of cell and gene therapies through our portfolio of cytokines and media supplements, along with a comprehensive suite of manufacturing services—including the production of proteins, media and buffers, and transfection and transduction reagents. We ensure your raw materials are as innovative as your therapies. GMP cytokines, Crypreservation media, Hemaotopietic and Mesechymal Cells and sources, Sterile Fill & Finish, Media & Buffers, Transfection Reagents, Human Plasma Derived Products, and Growth Factors

181 similar entities Type: SMB Activities: deeptech manufacturing biotech Technologies: Synthetic Biology

BRINGING YOUR SCIENCE TO LIFE CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more …

277 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Developing Innovative Cell Therapies Against Cancer Celyad Oncology is a biotechnology company focused on the discovery and development of tecnhlologies and platform for chimeric antigen receptor T cell (CAR T) therapies. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Immuno-Oncology, Cancer, Immnotherapy, shRNA multiplex, and CAR T-cells

149 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology